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        Pristane-induced plasma cell tumors and those 
that develop spontaneously in BALB/c IL-6 
transgenic mice carry either T(12;15) transloca-
tions between   IgH   and   c-Myc   (  1  –  3  ) or T(6;15), 
T(15;16) between   Ig   light chain and   Pvt  -1 (  4  ). 
These translocations activate and deregulate the 
transcription of the protooncogene   c-Myc   (  5  ), 
and they are found in   >  95% of the plasma cell 
tumors, strongly suggesting that deregulation 
of   c-Myc   is a critical, and possibly the initiating, 
event in their development. Most of the   IgH   
breaks occur in the S     or S     regions, although 
other rare rearrangements or insertions have been 
previously described (  6  –  10  ). 
  Activation-induced cytidine deaminase (AID), 
which is encoded by the gene   Aicda  , has been 
shown to be essential for physiological class 
switch recombination and somatic hypermuta-
tion (  11  –  13  ). Both class switch recombination 
and somatic hypermutation are associated with 
the generation of DNA double-strand breaks 
(DSBs). Two basic models have evolved to ex-
plain how AID contributes to the generation 
of these breaks. The fi  rst invokes deamination 
of cytidine in single-stranded DNA, followed 
by recruitment of uracil DNA glycosylase or 
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  Activation-induced cytidine deaminase (AID) is required for   immunoglobulin   (  Ig  ) class 
switch recombination and somatic hypermutation, and has also been implicated in translo-
cations between   Ig   switch regions and   c-Myc   in plasma cell tumors in mice. We asked if 
AID is required for accelerated tumor development in pristane-treated Bcl-xL transgenic 
BALB/c mice defi  cient in AID (pBx  Aicda    −  /  −  ). pBx  Aicda      −  /  −    mice developed tumors with a 
lower frequency (24 vs. 62%) and a longer mean latency (108 vs. 36 d) than AID-suffi  cient 
mice. The tumors appeared in oil granuloma tissue and did not form ascites. By interphase 
fl  uorescence in situ hybridization, six out of nine pBx  Aicda      −  /  −    primary tumors had T(12;15) 
and one had T(6;15) chromosomal translocations. Two tumors were transplantable and 
established as stable cell lines. Molecular and cytogenetic analyses showed that one had an 
unusual unbalanced T(12;15) translocation, with   IgH C       and   Pvt-1   oriented head to tail at 
the breakpoint, resulting in an elevated expression of   c-Myc  . In contrast, the second was 
T(12;15) negative, but had an elevated   N-Myc   expression caused by a paracentric inversion 
of chromosome 12. Thus, novel mechanisms juxtapose   Ig   and   Myc  -family genes in AID-
defi  cient plasma cell tumors. 2990 PLASMA CELL TUMOR DEVELOPMENT IN AID-DEFICIENT MICE | Kovalchuk et al.
day 140 77% of the mice had developed plasma cell tumors that 
were readily transplantable (5/5 tumors grew within 30 d). 
  The BALB/c-Bcl-xL mice were also crossed to C57BL/6 
and DBA/2. These strains, as well as their F1 hybrids with 
BALB/c, are resistant to plasma cell tumor induction by pris-
tane (  26  ) (  Fig. 1 A  ). In contrast, the incidence of plasma cell 
tumors in mice haploid for the Bcl-xL transgene was greatly 
increased, even though the latency was prolonged relative 
to that of pBxBALB/c mice. Thus, the Bcl-xL transgene was 
mismatch repair proteins, leading to the generation of DSB 
and error-prone repair (  14  –  16  ). There are also several lines 
of evidence that favor a second   “  RNA-editing  ”   hypothesis, 
which postulates that AID functions as an mRNA deami-
nase that edits a putative precursor RNA, converting it to an 
mRNA encoding an endonuclease that cleaves   IgH   switch 
regions (  17, 18  ). 
  Consistent with its role in creating DNA breaks in   IgH   
switch regions, AID has been implicated in the etiology of 
canonical   IgH  /  c-Myc   translocations (  19, 20  ). However, the 
role of AID in plasma cell tumor development has not been 
determined. In this study, we ask whether plasma cell tumors 
can be induced in   Aicda      −  /  −    mice by the intraperitoneal injec-
tion of pristane. 
  Most previous studies of   Aicda      −  /  −    mice used animals raised 
under specifi  c pathogen  –  free (SPF) conditions. It was shown 
earlier that the incidence of pristane-induced plasma cell tu-
mors is strikingly reduced in SPF-raised mice, and that high 
yields of these tumors require a conventional environment (  21  ). 
Preliminary experiments with conventionally raised pBALB/
c-  Aicda      −  /  −    resulted in deaths of the mice from a wasting syn-
drome that is attributed to an abnormal composition of gut 
fl  ora, excessive lymphoid neogenesis (  22  ), and reactivation of 
latent viruses. 
  To minimize these complications, we used an accelerated 
model of tumor induction. Previous studies showed that the 
time course for pristane-induced plasma cell tumor develop-
ment was markedly increased in mice carrying a Bcl-2 trans-
gene (  23  ). Furthermore, Cheung et al. showed that the 
3    E    -Bcl-xL transgene cooperates with enforced expres-
sion of   c-Myc   to accelerate plasma cell tumor formation (  24  ). 
In this study, we confi  rmed that constitutive expression of 
Bcl-xL greatly accelerated pristane-induced plasmacytoma 
development using BALB/c mice carrying a SV40-E    -Bcl-
xL transgene. 
  We backcrossed the Bcl-xL transgene onto a BALB/c-
  Aicda      −  /  −    background to determine if AID-defi  cient mice can 
be induced to develop plasma cell tumors. We report that 
absence of AID had an inhibitory eff  ect on plasma cell tumor 
induction by pristane. It resulted in a substantial delay in the 
emergence of atypical plasma cell tumors that did not grow 
in ascite form, had altered transplantability, and carried non-
canonical translocations between   c-Myc   and   IgH  . 
    RESULTS   
  Acceleration and augmentation of plasma cell tumor 
development in pristane-treated BALB/c-Bcl-xL (Bx) 
transgenic mice 
  Mice carrying the SV40-E    -Bcl-xL transgene, like Bcl-2 
transgenics (  25  ), spontaneously developed a low incidence of 
plasma cell tumors (19%) with long latencies of   >  300 d (  Fig. 
1 A   and   Table I  ).   Injection of pristane into BALB/c-Bcl-xL 
transgenic mice resulted in a marked acceleration and greatly 
increased incidence of plasma cell tumors arising in the oil 
granuloma (  Fig. 1 A  ).   These mice fi  rst developed ascites con-
taining tumor cells between 30 and 40 d after injection, and by 
  Figure 1.     Augmentation and acceleration of pristane (p)-induced 
plasma cell tumor formation by the Bcl-xL transgene. (A) The Bcl-xL 
transgene was backcrossed onto BALB/cAnPt. At N5 BALB/c-Bcl-xL (Bx) 
were crossed to C57BL/6 and DBA/2, and the F1 hybrids were injected 
with pristane: pBx (diamonds, blue); p(Bx x DBA/2)F1 (triangles, yellow); 
p(Bx xC57BL/6)F1 (X, green); pBALB/c (+, brown). Nonpristane injected 
controls: Bx (fi  lled squares, red); (Bx x DBA/2)F1 (squares with an x, laven-
der); (Bx x C57BL/6)F1 (fi  lled circles, orange). See   Table I   for numbers of 
mice and percentages of plasma cell tumors. (B) Incidence of plasma cell 
tumors as determined by histological appearance of foci, each contain-
ing 50 or more atypical plasma cells. Mice with one or more atypical 
foci were regarded as positive. Squares, black: plasma cell tumors in 
23/37 pBx transgenic mice. Diamonds, blue: plasma cell tumors in 8/33 
pBx  Aicda   − / −    mice.   JEM VOL. 204, November 26, 2007 
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these threatening complications, most of the mice had to be 
killed. Notably, none of the mice had ascites. Oil granulomas 
were found in pBx  Aicda      −  /  −    mice, but in smaller amounts than 
in pBx  Aicda    +   mice, and they did not appear to contain suspi-
cious tumorlike areas. Nonetheless, the oil granuloma tissues 
were harvested and transplanted into pristane-conditioned 
BALB/c mice or fi  xed for histological studies. Unexpectedly, 
histologic studies revealed that some of these mice had plasma 
cell tumors in the mesenteric oil granulomas. 8/33 (24.2%) 
of p  Aicda      −  /  −    mice were found to have evidence of plasma 
cell tumor formation in oil granuloma tissue after 72  –  149 d 
(mean latency of 108 d;   Fig. 1 B   and   Table II  ).   An additional 
pBx  Aicda      −  /  −    plasma cell tumor, 4987, was discovered in a 
separate study, but was not included in the incidence fi  gures 
for this experiment. 
  Plasma cell tumors induced by pristane characteristically 
spread from one site to another within oil granulomas. 3 of 
the neoplasms found in pBx  Aicda      −  /  −    mice involved   >  15 sites 
(advanced plasma cell tumors), 4 had 10 or more foci of atyp-
ical plasma cells (intermediate), and 2 had only 3  –  6 foci. The 
foci were located near or on peritoneal surfaces and involved 
multiple mesenteric polyplike structures, suggesting possible 
transperitoneal seeding (  27  ). 
  The pBx  Aicda      −  /  −    plasma cell tumors exhibited a spectrum 
of morphological types from lymphocytoid plasma cells (5000) 
to well-diff  erentiated plasma cells (4451) resembling Russell 
body cells (  Fig. 2  ).   There was also one example of a plasma 
cell tumor (4885) with morphological features typical of 
plasma cell tumors of   Aicda    +   or WT mice. Finally, consistent 
with defi  ciency of switched Ig classes in sera of humans and 
mice defi  cient in AID (  13  ), all of these plasma cell tumors 
were shown by immunohistochemistry to express IgM and 
Ig    , but no IgA or IgG as is typical of plasma cell tumors from 
AID-competent mice (unpublished data). 
  pBx  Aicda    +   mice developed plasma cell tumors that were di-
agnosed by the appearance of tumor cells in the ascites between 
50 and 130 d after pristane injection (mean latency of 86 d). 
able to augment and accelerate plasma cell tumor development 
in these genetically resistant strains. 
  Effects of pristane injection on survival of conventional 
BALB/c   Aicda      −  /  −    (p  Aicda      −  /  −   ) mice 
  Groups of conventionalized   Aicda       −  /  −    mice were raised on a 
diet with or without metronidazole to control the growth of 
anaerobic bacteria in the gastrointestinal tract (  22  ) (Table S1 
and Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20070882/DC1). At various intervals after the intra-
peritoneal injection of pristane, p  Aicda      −  /  −    mice began losing 
weight, developing a hunched posture and ruffl   ed fur. When 
weight loss or other signs became apparent, the mice were 
killed and autopsied. Others showed signs of a central nervous 
system (CNS) disorder, such as hind limb paralysis or ataxia. 
The cause of the CNS signs was not determined, but could be 
caused by activation of latent mouse hepatitis virus, which 
these mice are known to carry (unpublished data). The mean 
survival time for p  Aicda      −  /  −    mice was 130 d without and 155 d 
with metronidazole. The incidence of plasma cell tumors in 
the group without antibiotic was 38% (mean latency of 239 d) 
and with antibiotic was 32% (mean latency of 177 d). A single 
developing plasma cell tumor was found in the p  Aicda      −  /  −    
mice. Thus, the plasma cell tumors began appearing in AID-
competent mice long after most of the corresponding   Aicda      −  /  −    
mice had already died. Further, the incidence of plasma cell 
tumors was very low in the   Aicda      −  /  −    mice that did survive into 
the period when tumors commonly occur in WT mice. 
  Induction of atypical plasma cell tumors in pristane-treated 
BALB/c-Bcl-xL transgenic   Aicda      −  /  −    (pBx  Aicda      −  /  −   ) mice 
  To accelerate plasma cell tumor formation, we injected pris-
tane into BALB/c-Bcl-xL transgenic   Aicda      −  /  −    (pBx  Aicda      −  /  −   ) 
mice. These mice developed the aforementioned wasting 
syndrome, and many developed dyspnea caused by greatly 
enlarged superior mediastinal lymph nodes. These mice also 
exhibited lymphoid neogenesis (see below). As a result of 
    Table I.        Summary of induction studies 
Figure Pristane Background 
  genotype 
Bcl-xL 
  transgene 
  Aicda   
  geno-type 
PCT/total Mean 
  latent 
  period
Method 
  of 
  diagnosis 
  %   d 
1 A   −  BALB/c  +  + 4/21 (19%) 382 Cytofuge
1 A  + BALB/c N5  +   + 24/31 (77%) 66 Cytofuge
1 A  + BALB/c N5, LM    −   + 14/33 (38%) 193 Cytofuge
1 A  + (BALB/c N5 x C57BL)F1  +  + 32/44 (72%) 139 Cytofuge
1 A  + (BALB/c N5 x C57BL)F1    −   + 3/28 (10%) 269 Cytofuge
1 A  + (BALB/c N5 x DBA/2)F1  +  + 15/19 (79%) 187 Cytofuge
1 A  + (BALB/c N5 x DBA/2)F1    −   + 0/19 (0%)   − Cytofuge
1 B  + BALB/c  +  + 23/27 (62%) 36 Histology
1 B  + BALB/c    −     −  /  − 1/45  (2%) 132 Histology
1 B  + BALB/c N7  +    −  /  − 8/33  (24%) 108 Histology
B/c, BALB/c; LM, littermates; N, backcross generation; PCT, plasma cell tumor.2992 PLASMA CELL TUMOR DEVELOPMENT IN AID-DEFICIENT MICE | Kovalchuk et al.
cell tumors also diff   ered from tumors of AID-competent 
mice in their ability to grow in secondary recipients. 
  Exaggerated lymphoid neogenesis in tissues 
of pBx  Aicda      −  /  −    mice 
  When compared with the p  Aicda      −  /  −    mice, the pBx  Aicda      −  /  −    
mice had additional complications that were caused by 
exces  sive lymphoid hyperplasia in the form of lymphoid aggre-
gates, which were previously described as lymphoid neogenesis 
(  28, 29  ). Numerous lymphoid aggregates were found in the wall 
of the small intestine and the lamina propria of the intestinal 
villi, with some presenting as isolated lymphoid follicles (  22, 30  ). 
Because none of the pBx  Aicda      −  /  −    mice developed ascites, the 
diagnosis of plasma cell tumors in these mice had to be made 
retrospectively by microscopic analyses of tissue sections. To 
make direct comparisons with other groups, we examined 
tissue sections from 37 pBx  Aicda    +   mice for atypical plasma 
cell focus development between days 14 and 49 after pristane 
(  Fig. 1 B  ). Mice with one or more foci were considered pos-
itive. The plasma cells in these foci were hyperchromatic and 
resembled cells characteristic of plasma cell tumors. The mean 
latency after pristane for tumor development in the 21 posi-
tive mice was 36 d. 
  pBx  Aicda      −  /  −    plasma cell tumors proved to be diffi   cult 
to transplant, whereas plasma cell tumors of pBx mice were 
readily transplantable and grew out within 30 d. We con-
sider completely transformed plasma cells to be transplant-
able. There are several possible explanations for this. First, 
we were not able to establish the clonality of the primary tu-
mors in pBxAicda    −  /  −    mice by immunohistochemistry, PCR, 
or Southern blotting. Second, in mice with few foci (4451, 
5000, and 5047), it is possible that the transplanted tissue 
fragments did not contain a tumor focus (  Table II  ). Third, 
the more advanced cases (4885 and 4961) that did grow in 
transplant diff  ered from pBx  Aicda    +   tumors by taking 4 mo to 
grow out in pristane-conditioned BALB/cAn mice. Further-
more, one of the two more advanced tumors (4961) did not 
grow out in eff  orts to passage it a second time. This could be 
evidence of incomplete transformation. 
  Both transplantable tumors (4885 and 4961) were estab-
lished in tissue culture as cell lines. They exhibited a mature 
plasma cell phenotype (CD45    −   , CD138  +  , PC-1  +  , CD19    −   , 
and CD23    −   ), secreted IgM, and were clearly of donor origin, 
as they were shown to carry the Bcl-xL transgene by PCR 
analysis and carried both   Aicda      −  /  −    alleles. In contrast to all 
previously studied mouse plasma cell tumors, both cell lines 
were found to express CD5 cell surface marker, and 4961 had 
intermediate expression of CD11b by FACS analysis (unpub-
lished data). We conclude that atypical plasma cell tumors 
develop in pBx  Aicda      −  /  −    mice and that they appear at a much 
slower rate than in AID-suffi   cient mice. pBx  Aicda      −  /  −    plasma 
    Table II.        Characteristics of plasma cell tumors in pBx  Aicda   − / −    mice 
Mouse# Post 
  pristane
Oil 
  granuloma 
  no. foci
Transplant to 
  pristane-primed 
  recipient
FISH
  d 
3935 77 20 no growth  + T(12;15)
4885 72 20  + 4 mo  + T(12;15)
4451 102 6 no growth  + T(12;15)
4961 111 15  + 4 mo Inv (12)
4592 149 13 no growth negative
5000 84 3 no growth  + T(12;15)
5008 133 13 no growth + T(6;15)
5047 135 6 no growth + T(12;15)
4987 127 11 no growth  + T(12;15)
  Figure 2.     Photomicrographs of four plasma cell tumors arising in 
pBx    Aicda  −  /−            mice that show variations in plasma cell morphology. 
4885 resembles tumors found in WT mice. The most undifferentiated, 
5000, resembles lymphocytoid plasma cells. They have the least amount 
of cytoplasm, which consists of a thin rim around the nucleus. 4451 con-
tains many cells with Russell body  –  like features, as well as cells with 
  mature plasma cell morphology. 4961 is an early plasma cell tumor show-
ing many small plasma cells that differ in size from the common types of 
plasma cell tumors that are well known to contain near tetraploid num-
bers of chromosomes. Bar, 20    m.   JEM VOL. 204, November 26, 2007 
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Cells were examined using 3D view (  Fig. 3, C and D  ), and 
  IgH  /  c-Myc   gene colocalization was confi  rmed. 
  The proportion of cells with fusion signals in pBx  Aicda      −  /  −    
plasma cell tumors (3935, 4451, 4987, 4885, 5000, and 5047) 
ranged from 34 to 63%. In pBx  Aicda    +/  −    plasma cell tumors, 
the proportions ranged from 29 to 57% (Table S2, available 
at http://www.jem.org/cgi/content/full/jem.20070882/DC1). 
Samples from diff  erent parts of a tumor showed variations in 
the proportion of positive cells, which may be caused by varying 
contributions of stromal or other nontumor cells. 
  As controls, fi  ve samples of lymphoid hyperplasia or ex-
tramedullary myelopoiesis, taken from the same oil granu-
loma tissue sections, showed 0  –  2.6% of cells with a fusion 
signal. These data were used to establish a value of 4.1% (four 
standard deviations above the mean) as identifying transloca-
tion-bearing plasma cell tumors. Based on these calculations, 
three additional plasma cell tumors from pBx  Aicda      −  /  −    mice 
(4961, 5008, and 4592) were scored as T(12;15) negative. 
  Tissue sections of tumors negative for T(12;15) were hy-
bridized with probes specifi  c for   IgK   on chromosome 6 and 
for   c-Myc   to detect T(6;15), which is a translocation found at 
lower frequency than T(12;15) in plasma cell tumors of AID-
suffi   cient mice. Tumor 5008 was positive for   Ig      /  c-Myc   co-
localization, with 55% of cells positive for fusion signals, this 
is in comparison to a plasmacytic focus from the same sec-
tion, with only 3.5% positive cells. 
  PCR and Southern blot hybridization studies of primary 
plasma cell tumors and cell lines 
  The frequency of T(12;15) in pristane-induce plasma cell tu-
mors of WT mice is     80% (  31  ).The vast majority of either 
Many of these aggregates contained germinal center  –  like 
structures with a central PNA  +   zone surrounded by B220  +   
lymphocytes. These aggregates were rarely seen in p  Aicda      +  /  −    
mice. Most of the p  Aicda      −  /  −    mice had splenomegaly, along 
with enlarged mesenteric lymph nodes and Peyer  ’  s patches. 
Many developed dyspnea caused by greatly enlarged superior 
  mediastinal lymph nodes resulting from the transport of pristane 
oil out of peritoneal space or, in some cases, to the formation 
of lymphoid tissues in the lungs (Fig. S2 A, available at http://
www.jem.org/cgi/content/full/jem.20070882/DC1). 
  An important characteristic of the oil granulomas in pBx  -
Aicda      −  /  −    mice was the presence of variable, but usually large, 
numbers of these lymphoid aggregates. Most contained PNA  +   
lymphocytes and resembled the aggregates of lymphoid neo-
genesis (Fig. S2, B  –  D). Many of the neogenic lymphoid aggre-
gates were associated with plasma cell formation in the oil 
granuloma, suggesting that these might also represent initiating 
sites for plasma cell tumor development. However, a clear his-
tological link to plasma cell tumor formation was not found. 
  Most plasma cell tumors of pBx  Aicda      −  /  −    mice carry 
translocations between   IgH   and   c-Myc   
  Focal plasma cell tumors were fi  rst found in histological sec-
tions stained with hematoxylin and eosin. The corresponding 
sites in serial sections were examined by fl  uorescence in situ 
hybridization (FISH), and photographed, and the number of sig-
nals per cell was recorded. Intact diploid nuclei exhibited 2 red 
(  IgH  ) and 2 green (  c-Myc  ) signals, and cells with T(12;15) had 
1 red, 1  –  2 green, and 1 fused (yellow) signal (  Fig. 3, A and B  ).   
Many nuclei had fewer signals, as all chromosomes were 
not uniformly included in the plane of the 5-    m section. 
  Figure 3.     Interphase FISH on tissue sections showing         IgH/c-Myc         colocalization in pBx    Aicda  −  /−            plasma cell tumor 4885. (A and C) Two- and 
three-dimensional photomicrographs of interphase nuclei from a cell with no evidence of T(12;15) translocation: two red (  IgH  ) and two green (  c-Myc ) 
signals. (B and D) A cell with a fused signal indicative of T(12;15), doublet Red (  IgH  ) resulting from hybridization to two sister chromatids, and two green 
(  c-Myc  ) signals. Grid, 1     m. Bars, 1    m.   2994 PLASMA CELL TUMOR DEVELOPMENT IN AID-DEFICIENT MICE | Kovalchuk et al.
gion degenerate primers. We were unable to amplify products 
containing   c-Myc   and   IgH   chimeric sequences (unpublished 
data). As controls, we analyzed seven pBx  Aicda    +/  −    tumors, 
fi  ve of which were positive (Table S3, available at http://www
.jem.org/cgi/content/full/jem.20070882/DC1). Thus, the 
der(12)T(12;15) or der(15)T(12;15) breakpoints can be ampli-
fi  ed by PCR (  32, 33  ). To determine the nature of the trans-
locations in pBx  Aicda      −  /  −    plasma cell tumors, we performed 
PCR reactions using long PCR (covering VDJ-E   , C   , C   1, 
C    2b, C    2a, C    , and C    ), as well as PCR with switch re-
  Figure 4.     Molecular and cytogenetic analysis identifi  es the T(12;15) chromosomal translocation in the pBx    Aicda  −  /−            cell line, 4885. (A) A 
representative karyotype of cell line 4885 analyzed by SKY shows a subtle translocation involving chromosome 12 and 15 as indicated by the arrow. 
(B) FISH using whole chromosome painting probes confi  rms a T(12;15) (arrow). Metaphase chromosomes are DAPI-stained. The normal chromosome 12 is 
depicted in red, and the normal chromosome 15 is shown in green. (C) FISH with gene-specifi  c probes confi  rmed the involvement of   c-Myc   and   IgH   in  the 
chromosomal rearrangement. Within the DAPI-stained metaphase, probes for   c-Myc   (green) and   IgH   (red) are colocalized on the abnormal chromosome 
(arrow). Additionally,   c-Myc   signals are present on the normal chromosome 15, whereas the signal for the   IgH   gene appears on the normal chromosome 12. 
(D) aCGH profi  le of the 4885 cell line. Locations of   IgH C m    (chromosome 12, top plot) and   Pvt-1   (chromosome 15, bottom plot) are indicated by arrows 
pointing up. Translocation breakpoints (Tx) are depicted by arrows pointing down. Bars, 5    m.   JEM VOL. 204, November 26, 2007 
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aligned to the regions of gains and reconfi  rmed their presence 
on all copies of chromosome 15 and der(12)T(12;15). BAC 
62I2 that corresponds to the distal portion of chromosome 15 
in the region showing no gain, hybridized only to 2   “  normal  ”   
copies of chromosome 15. The schematic structure of der(12) 
chromosome is presented in Fig. S4. 
  Because the location of the translocation breakpoint was 
scrambled for chromosome 15 and straightforward for chro-
mosome 12, we resorted to inverse PCR using   IgH C       primers 
to amplify the junction. Sequence analysis identifi  ed the 
breakpoint location on chromosome 12 just 211 bp upstream 
of the fi  rst exon of   IgH C      , which is very close to the break-
point predicted by aCGH (see above). The chromosome 15 
breakpoint was     75 kbp downstream of   c-Myc  , which was 
joined with   IgH   in a head-to-tail orientation that is unusual 
for T(12;15) translocations. This fi  nding suggests that chro-
mosome 15 underwent a paracentric inversion involving the 
  c-Myc   locus before or during illegitimate recombination with 
chromosome 12 (Fig. S4). Consistent with the aCGH data, 
the   Pvt-1   locus was allocated to der(15) and cannot be de-
tected with RP23-96F18 BAC on der(12) (Fig. S4). ABPC60 
is the only known plasma cell tumor with a T(12;15) to have 
the breakpoint 3     of   c-Myc   (  9  ). Moreover, before this study, 
the closest known breakpoint to   IgH C       (914 bp 5    ) was in 
a BALB/c pristane-induced tumor PCT 4130 (unpublished 
data). We conclude that the breakpoint location in 4885 
is atypical compared with other mouse plasma cell tumors 
with T(12;15). 
  For the pBx  Aicda      −  /  −    cell line 4961, 10 complete meta-
phases were analyzed by SKY and showed a near diploid kar-
yotype of 40, X, T(1;10), +6, In(  12  ), T(10;1) (  Fig. 5 A  ).   One 
copy of chromosome 12 showed an abnormal inverted DAPI 
pattern suggestive of a paracentric inversion (  Fig. 5 B  ). We 
performed additional metaphase FISH studies to identify the 
genes aff  ected by the inversion. Using FISH with 3      IgH  - 
(green) and 5      IgH  -specifi  c (red) probes, we uncovered the 
relocation of   IgH   3     locus control region from it  ’  s usual telo-
meric site toward the centromere ( Fig. 5 C ) and colocalization 
of the 3      IgH   probe (green) with a BAC probe for   N-Myc   (red) 
on inv(12) (  Fig. 6 D  ).   Ideograms of the normal and the in-
verted chromosome 12 are drawn in   Fig. 5 D  . An aCGH 
analysis of chromosome 12 did not reveal any sizable dele-
tions associated with the inversion or amplifi  cations (unpub-
lished data). Consistent with the PCR and Southern blot 
analysis data described previously, we propose that the inver-
sion must have occurred upstream of the rearranged VDJ seg-
ment. It is not yet clear if the inversion involved the expressed 
or the nonexpressed allele. The break site in the vicinity of 
  N-Myc   must have occurred within 200 kbp telomeric to the 
gene. A proposed structure of this novel chromosome 12 in-
version in 4961 is presented in Fig. S4. 
  Up-regulated expression of   c-Myc   or   N-Myc   in pBx  Aicda      −  /  −    
cell lines 
  To establish that the observed genomic rearrangements, in-
deed, resulted in activation of adjacent oncogenes, we compared 
translocations in pBx  Aicda      −  /  −    mice take place in unusual loca-
tions and are unlikely to involve switch regions. 
  Southern blots performed with DNA isolated from cell 
lines 4885 and 4961 showed that the   c-Myc   gene was in 
germline confi  guration and not amplifi  ed (unpublished data). 
Analysis of J  H   rearrangements in these tumors revealed the 
absence of a germline band and the presence of two rear-
ranged bands in the translocation-negative cell line (4961) and 
a single rearranged band in the T(12;15)-positive cell line 
(4885; Fig. S3, available at http://www.jem.org/cgi/content/
full/jem.20070882/DC1). This indicates that in 4885, one 
copy of the J-C intron was completely lost as the result of a 
nonreciprocal T(12;15) translocation. 
  Consistent with the Southern blot data, 4885 carried and 
expressed a single rearranged heavy chain allele (Vh J558,
17-DSP2.13-Jh4). 4961 carried both alleles; one productively 
rearranged (J558.41-DSP2.7-Jh2) and another with stop codons 
(J558.41-DSP2.2-Jh2). DNA sequences of expressed V  H  D  H  J  H   
and V  k  J  K   genes had no mutations (unpublished data). 
  pBx  Aicda      −  /  −    plasma cell tumor cell lines exhibit atypical 
  IgH/Myc   rearrangements 
  The pBx  Aicda      −  /  −    cell line derived from tumor 4885 was ana-
lyzed by spectral karyotyping (SKY) and showed a near dip-
loid karyotype of 39  −  42, XY, +1, +15, der(12)T(12;15) in 
at least 15 metaphase spreads (  Fig. 4 A  ).   The translocation 
was rather subtle because the telomeric portion of chromo-
some 15 appeared smaller then usual. FISH analysis using 
whole chromosome painting probes for mouse chromosome 
12 and 15 confi  rmed the presence of a T(12;15) (  Fig. 4 B  ). 
Further analyses with gene-specifi  c probes identifi  ed a juxta-
position of   IgH   and   c-Myc   (  Fig. 4 C  ), the absence of a recipro-
cal chromosome der(15)T(12;15) and the presence of an extra 
copy of   “  normal  ”   chromosome 15. Therefore, a nonrecipro-
cal T(12;15) may have originated in a cell with a trisomy of 
chromosome 15, which is a frequent occurrence in mouse B 
cell and T cell lymphomas, but is almost never seen in diploid 
mouse plasma cell tumors (  34  ). 
  Because of the unbalanced T(12;15) in 4885, we used 
NimbleGen  ’  s high-resolution array comparative genomic 
hybridization (aCGH) to map translocation breakpoints. 
Analysis of an array CGH profi  le of chromosome 12 shows 
gross deletions in the 5      IgH   locus, which is typical for VDJ 
recombination events (  Fig. 4 D  , top plot). Additionally, it 
shows the loss of one copy of the telomeric portion of chro-
mosome 12 (log  2   ratio of   −  0.5) starting at     650 bp upstream 
of the fi  rst exon of   IgH C      , which indicates the approxi-
mate position of the translocation breakpoint (  Fig. 4 D   and 
Fig. S4, available at http://www.jem.org/cgi/content/full/
jem.20070882/DC1). This deletion is also consistent with 
the loss of der(15)T(12;15). 
  In contrast, alterations of chromosome 15 appear to be 
much more complex and show six regions of gains, including 
one in the telomeric portion (Log  2   ratio of 0.25;   Fig. 4 D  , 
bottom plot). This fi  nding suggests multiple deletions of der(12). 
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The pBx-  Aicda      −  /  −    mice did not develop ascites, a process that 
facilitates diagnosing plasma cell tumors by paracentesis. Thus, 
one of the important signs of tumor development was not 
present. Finally, most of these tumors had not progressed to 
become fully autonomous malignancies. In summary, AID is 
essential for the usual development and progression of pristane-
induced plasmacytomas. Nevertheless, atypical plasma cell tu-
mors can arise in the absence of AID. 
  Using interphase FISH in paraffi   n sections, we found evi-
dence of T(12;15) chromosomal translocations in 6 of the 
9 pBx  Aicda      −  /  −    tumors studied (  Table II  ). In these samples, 
35  –  63% of the cells in the tumor-containing regions exhibited 
fusion signals that were interpreted as indicative of T(12;15) 
translocations. Our initial expectation was that in the absence 
of AID the   Ig    /Pvt-1   recombination would be preferred. 
However, we found a T(6;15) in only one tumor, 5008. 
expression of   c-Myc   and   N-Myc   mRNA in pBx  Aicda      −  /  −    and 
pBx  Aicda    +/+   cell lines using quantitative PCR (qPCR). Ex-
pression of   c-Myc   was comparably elevated in all cell lines 
  except for 4961 that expressed a high level of   N-Myc   message 
(  Fig. 6  ). 
    DISCUSSION   
  In this study, we showed that plasma cell tumors can be 
  induced in pristane-treated BALB/c-Bcl-xL   Aicda      −  /  −    mice. 
These tumors, however, are characterized by a reduced fre-
quency and prolonged latency when compared with plasma 
cells tumors of pristane-treated AID-competent mice. The 
plasma cell tumors in the pBx  Aicda      −  /  −    mice also diff  ered from 
those arising in pBx  Aicda    +  , as six were apparently in early or 
intermediate stages of progression and most could be diag-
nosed only retrospectively by studies of histologic sections. 
  Figure 5.     Cytogenetic analysis of pBx    Aicda  −  /−            cell line 4961. (A) SKY identifi  es a reciprocal T(1;10) translocation and trisomy 6. (B) Inverted DAPI 
staining and spectral image of normal (left) and inverted (right) chromosome 12 showing different band pattern on the inverted chromosome. (C) FISH 
with 3    IgH   (green) and 5    IgH   (red)  gene-specifi  c probes identifi  es one normal chromosome 12 (left) and breakage of the   IgH   locus on the other chromo-
some 12 (right) as the result of a paracentric inversion. (D) FISH shows colocalization of 3    IgH   (green) and   N-Myc   (red) signals on inverted chromosome 
12 (right) and their usual location at opposing ends on normal chromosome 12 (left). (E) Ideograms showing a normal chromosome 12 (left) and chromo-
some 12 with a paracentric inversion (right).     JEM VOL. 204, November 26, 2007 
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Myc   illegitimate recombinations in fi  ve samples containing 
pBx  Aicda      −  /  −    plasma cell tumors by using PCR primers used 
in the Unniraman study or any other primer combination 
with the exception of C     and C    3 (Table S4, available at 
http://www.jem.org/cgi/content/full/jem.20070882/DC1). 
Our results are in agreement with those of Ramiro et al. (  19  ), 
who, using another plasma cell tumor induction system, did 
not detect canonical   IgH/c-Myc   translocations in IL6-trans-
genic   Aicda    −  /  −      mice. 
  Molecular and cytogenetic analyses of illegitimate recom-
binations in 4885 and 4961 pBx  Aicda      −  /  −    cell lines showed no 
involvement of switch regions or sequences in close proxim-
ity to   c-Myc  . This diff  ers from most T(12;15)-positive plasma 
cell tumors in AID-competent mice (  5  ). A mechanism for 
generating   “  untargeted  ”   single-strand DNA breaks and DSB, 
one that does not depend on special features of switch regions 
and also involves   c-Myc  , is a potential explanation for our 
fi  ndings. This possibility is supported by earlier studies show-
ing that occasional pristane-induced plasma cell tumors in 
BALB/c mice have unusual rearrangements of   c-Myc   and   Ig   
genes (  6  –  10  ). Although our experiments confi  rm the impor-
tance of AID in mediating canonical   IgH  /  c-Myc   transloca-
tions, they also establish the existence of additional mechanisms 
that can lead to illegitimate recombination of   Ig   genes with 
an oncogene in the absence of AID. 
  Several studies have described B cells and B cell lympho-
mas with   “  unusual  ”   illegitimate recombinations of chromo-
somes 12 and 15. These studies have used mice with two 
types of genetically engineered abnormalities. The fi  rst in-
volved mice defi  cient in proapoptotic signaling as a result of 
homozygosity for a   p53   knockout or by constitutive ex-
pression of an antiapoptotic gene, either   Bcl-2   or   Bcl-xL  . The 
second category is associated with defects in genes involved 
in DNA damage control (  scid  ,   ATM  ,   H2AX  ,   53BP-1  , and 
  Nbs-1  ) or in nonhomologous end joining (  XRCC4  ,   Ligase IV  , 
  Ku70/80  , DNA   PKcs  , and   Artemis  ) (  39  –  46  ). Tumors associ-
ated with these defects predominantly occurred in pro  –  B 
cells and contained   IgH  /  c-Myc   chromosomal translocations. 
Amplifi  cations, termed complicons, that generated additional 
illegitimate   IgH  /  c-Myc   recombinations, sometimes three-way, 
have also been described in these tumors (  41, 47  –  49  ). It was 
proposed that the DSBs leading to these illegitimate recom-
binations were associated with RAG1/2 activity, as they oc-
curred between V  H   and C     (  41, 47, 48  ). The mechanism of 
DNA end joining in these tumors may involve the recogni-
tion of microhomologies (  50, 51  ). 
  Alternative pathways of generating DSBs may target the 
genomes of B cells, and could be responsible for the aberrant 
generation of T(12;15) seen in pBx  Aicda      −  /  −    mice. It has been 
shown that microenvironments that produce oxidants may 
cause DSBs or lead to neoplastic transformation (  52, 53  ). The 
pristane-induced oil granuloma in BALB/c mice contains an 
abundance of neutrophils, particularly in the early stages of its 
formation, which generate oxidants and other products that 
have been shown to damage DNA (  54  ). Shacter et al. cocul-
tured plasma cell tumor cells with purifi  ed neutrophils in vitro 
A surprising fi  nding was the activation of   N-Myc   by a para-
centric inversion of chromosome 12 in tumor 4885. The sole 
previous example of   N-Myc   activation and deregulation in 
mouse plasma cell tumors resulted from the juxtaposition of 
  Ig       and   N-Myc   loci in an exceptional mouse plasma cell tu-
mor, ABPC-132, which carries a reciprocal T(6;12) translo-
cation (  35  ). Functional homology between   N-Myc   and   c-Myc   
in mouse plasma cell tumor development was previously shown 
(  36  ). However,   N-Myc   is normally expressed only during the 
early stages of B cell development, and was found to be 
coamplifi  ed with   IgH   in B cell progenitor tumors that de-
velop in mice defi  cient for both   p53   and   Artemis   (  37  ). Thus, 
the majority of   Aicda      −  /  −    plasma cell tumors similar to those 
developing in their AID-suffi   cient counterparts are predis-
posed to T(12;15) translocations. 
  Unniraman et al., using highly sensitive PCR methodol-
ogies, recently studied lymphoid tissues in pristane-treated 
BALB/c   Aicda      −  /  −    mice to determine if they contained evi-
dence of switch-related T(12;15) (  38  ). Sequences of the 
junctional fragments obtained from the tissues harvested at 
2  –  4 wk after pristane showed that breakpoints occurred in 
  IgH   switch regions. They did not fi  nd similar PCR fragments 
3  –  5 mo later. It was not determined if these tissues contained 
plasma cell tumor cells. The explanation for these fi  ndings 
awaits further clarifi  cation. Although we did not study the 
early response to pristane, we were not able to detect   IgH  /  c-
  Figure 6.     Comparison of     c-Myc     and     N-Myc     transcript levels in 
pBx    Aicda  −  /−            cell lines 4961 and 4885 to pBx    Aicda  +/+          controls. 
(A) Summary of qPCR analysis of   c-Myc   and   N-Myc  . Numbers indicate the 
log2 transformed fold change. Data are mean expression from three inde-
pendent experiments. (B) Agarose gel electrophoresis of qPCR products. 
10     l of qPCR reaction were loaded on 2% agarose gel and visualized by 
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BALB/c-Bcl-xL transgenic mice. The   Aicda      −  /  −    mice developed by Muramatsu 
et al. (  12  ) were backcrossed four or more generations onto BALB/c(Kyoto) 
in Kyoto University and transferred to the NCI in 2003 as SPF mice. 
In 2004, they were introduced into the NCI conventional facility, where 
they were maintained in fi  lter-top cages and fed sterile water and a bacon-
fl  avored diet that contained 138 mg/kg metronidazole (Bioserve) to control 
the microbial fl  ora. BALB/cAnPt-Bcl-xL transgenic mice were crossed to 
BALB/c(Kyoto)-  Aicda    +/  −    mice at backcross N4, and the F1 hybrids were 
crossed to each other to produce F2. The following six genotypes were ob-
tained: Bcl-xL  +/  −      Aicda    +/+  ,   +/  −   , and     −  /  −   ; WT   Aicda    +/+  ,   +/  −   , and     −  /  −   . Mice of 
all six genotypes were inoculated intraperitoneally with 0.4 or 0.5 ml pris-
tane (Aldrich Chemicals) at 2 mo of age, and a second injection of pristane 
was given 60 d later. 
  Sample preparation.     Tissues were fi  xed in Fekete  ’  s modifi  ed Telleysniczky  ’  s 
fl  uid (70% ethanol/formalin/glacial acetic acid in 20:2:1 parts) for 12  –  48 h 
and transferred to 70% ethanol in buff  ered saline. These specimens were 
embedded in paraffi   n and sectioned at 4  –  5     m by HistoServ. To prepare 
metaphase chromosomes     10  7   cultured cells were fi  rst lysed and then fi  xed 
in 3:1 methanol/acetic acid solution. An aliquot of the suspension was dropped 
onto a glass slide in a controlled temperature (20  –  25  °  C) and humidity (45  –  55%) 
environment of a Thermotron. Total RNA and genomic DNA were iso-
lated according to the manufacturer  ’  s instructions using TRI reagent (Sigma-
Aldrich) and Purigene system (Gentra Systems) correspondingly. cDNA was 
obtained using a kit from Roche. 
  Plasma cell tumor diagnosis.     Plasma cell tumors in pristane-treated 
BALB/c mice were diagnosed using Wright-Giemsa  –  stained cytofuge prep-
arations of ascites. The presence of 10 tumor cells per fi  eld was scored as a 
positive. Most positive mice lived for several weeks, and the number of 
  tumor cells increased to   >  100 per cytofuge fi  eld. Because pBx  Aicda      −  /  −    mice 
did not develop ascites, we used hemotoxylin and eosin  –  stained sections of 
oil granulomas to determine the number of foci with 50 or more atypical 
plasma cells. 
  Transplantation and in vitro culture.     Tumor transplants were initiated 
by the injection of fi  nely minced oil granuloma tissue into syngeneic BALB/
cAnPt mice that had been injected intraperitoneally with 0.2  –  0.5 ml pristane 
1  –  15 d before transplantation. Cell lines were established from generation 1 
transplants by culturing in complete RPMI 1640 medium supplemented 
with 10% fetal calf serum and 10 ng/ml of IL-6. To ensure that the cell lines 
were not derived from plasma cell tumors of host origin, the tumor tissues 
were shown by PCR to carry the human Bcl-xL transgene (  68  ) and both 
targeted alleles of   Aicda   (  12  ). 
  Immunohistochemistry, ELISA, and FACS.     PNA (Vector Labora-
tories), anti-B220 (BD Bioscience), -IgM, -IgG, -IgA, and -Ig     (Southern-
Biotech) were all conjugated to biotin and reacted directly with sectioned 
tissue, followed by avidin conjugated to either alkaline phosphatase or per-
oxidase. Standard ELISA isotyping techniques were applied using mouse 
  serum or concentrated tissue culture supernatant as the antigen at an initial 
dilution of 1:500. We used goat anti  –  mouse IgA, IgG  1  , IgG  2a  , IgG  2b  , IgG  3  , 
and IgM HRP-conjugated antibodies (SouthernBiotech). Cell surface mark-
ers were analyzed using a FACSCalibur (Becton Dickinson) after the cells 
were stained with FITC-, PE-, APC-, or PerCP-conjugated antibodies 
  specifi  c for mouse CD45, CD19, CD138, PC-1, CD23, CD5, and CD11b 
(BD Biosciences). 
  Cytogenetic analysis of plasma cell tumors.     SKY was performed as 
  previously described (  69  ). SKY image acquisition was performed using the 
SpectraCube SD200 (Applied Spectral Imaging) connected to an epifl  uorescence 
microscope (DMXRA; Leica). Image analysis was done using SKYVIEW 
program version 1.6.2 (Applied Spectral Imaging). FISH was performed on 
metaphase chromosomes and interphase nuclei according to standard protocols 
(http://www.riedlab.nci.nih.gov/protocols.asp#h3) using whole-chromosome 
and found DNA damage in the target cells (  55  ). Some oxi-
dants may arise from endogenous metabolism (  56, 57  ). Also 
the   “  endogenous DSB  ”   process occurs during normal DNA 
replication generating an estimated 50 DSB/nucleus in a cell 
cycle (  58  ). We are currently unaware of the tissue site in 
which these DSBs take place. It could be in an extraperito-
neal site, such as bone marrow, spleen, or gut-associated lym-
phoid tissue, or in the oil granuloma itself. 
  The roles played by enforced expression of Bcl-xL or Bcl-2 
in the B lineage and the mechanisms by which they contrib-
ute to accelerating plasma cell tumor development are not 
established. The Bcl-xL transgene, as shown by Fang et al. 
(  59  ), acts during early B cell development in the bone mar-
row to give a 4  –  5 fold expansion of the pro-B cell compart-
ment and permits the survival of pro-B cells that have 
undergone nonproductive V-D-J rearrangements and exten-
sive   D  H     or   J  H     deletions (  59, 60  ). Transgenic Bcl-xL may also 
exert important eff  ects in peripheral B cells and plasma cells. 
  In this study, enforced expression of Bcl-xL under the 
control of the E     enhancer and SV40 promoter activates and 
expresses an antiapoptotic protein, and it acts as a functional 
equivalent to homozygosity for a null mutation of   p53  . Al-
though the pathway of action of p53, a transcriptional trans-
activator, and Bcl-xL, an inhibitor of mitochondrial apoptosis 
(  61  ), may diff  er, they potentially accomplish a common end 
result, which is a failure to eliminate cells that have experi-
enced illegitimate recombinations, which may mark the ini-
tiation of neoplastic progression. It should be noted, however, 
that p53 has many other functions such as governing cell 
cycle checkpoints and DNA replication (  62  ). In addition, 
p53 defi  ciency may promote DNA amplifi  cations (  63, 64  ). 
Ramiro et al. have postulated that there may be a surveillance 
mechanism mediated by p53 for detecting and eliminating 
cells that carry translocations ( 20  ). The constitutive expression 
of the antiapoptotic factor Bcl-xL may promote the survival 
of cells with T(12;15) that express relatively large amounts of 
Myc that otherwise would drive the cells into apoptosis (  65, 
66  ). B cells that harbor these translocations are able to prog-
ress slowly into atypical plasma cell dyscrasias reminiscent of 
indolent states of B cell neoplasia in humans. We conclude 
that rapid development of malignant plasma cell tumors with 
reciprocal T(12;15) does require AID, and that in AID defi  -
ciency other, less effi   cient mechanisms can be used to bring 
  c-Myc   and   Ig   genes into juxtaposition. The reason why re-
combinations between   IgH   and   c-Myc   occur so regularly in 
mouse plasma cell tumor formation is thought provoking and, 
as yet, an unexplained problem. 
    MATERIALS AND METHODS   
  Mice.     All animals were maintained under NCI IACUC-approved protocols 
LG023, LG024, and LG025. The mice were fed Purina Mouse Chow 5001 
ad libitum and sterilized acidifi  ed drinking water. The SV40-E    -Bcl-2 
transgene was originally developed by Strasser et al. (  25  ) and modifi  ed by 
Grillot et al. (  67  ) by replacing human Bcl-2 with human Bcl-xL. The SV40-
E    -Bcl-xL transgene, which was originally developed on hybrid backgrounds, 
was introgressively backcrossed onto conventionally raised BALB/cAnPt 
mice for six generations in the Laboratory of Genetics (NCI) to generate JEM VOL. 204, November 26, 2007 
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with P  32  -labeled mo  Myc   #303 or pJ11 probes provided by K. Huppi (NCI, 
Bethesda, MD). Images were scanned using the Typhoon imaging system 
(Molecular Dynamics). 
  Online supplemental material.     Fig. S1 is a graphical representation of 
survival and tumor incidence in pristane-injected pBx  Aicda      −  /  −    mice with 
or without antibiotic treatment. Fig. S2 presents histological evidence of 
exaggerated lymphoid neogenesis in lungs and oil granuloma tissue of 
pBx  Aicda      −  /  −    mice containing multiple germinal center  –  like structures. Fig. S3 
shows clonal Jh rearrangements in pBx  Aicda      −  /  −    cell lines identifi  ed by 
Southern blotting. Fig. S4 is a scheme depicting the molecular structure of 
genetic alterations in pBx  Aicda      −  /  −    cell lines. Table S1 shows a comparison 
of plasma cell tumor incidence in p  Aicda    +/  −    vs p  Aicda      −  /  −    mice. Table S2 
presents summary of FISH data showing proportions of IgH/c-Myc fusion 
signals in tissue sections. Table S3 shows results of PCR screening of AID-
suffi   cient Bcl-xL-transgenic mice for T(12;15)-translocation positive clones, 
and Table S4 provides sequences and positions of primers used for the 
screening. The online version of this article is available at http://www.jem
.org/cgi/content/full/jem.20070882/DC1. 
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